HealthcareServices

Global Personalized Ophthalmology Therapies Market Forecast 2026–2035: Long-Term Growth Insights

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the personalized ophthalmology therapies market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Personalized Ophthalmology Therapies Market from 2026 to 2030?

The personalized ophthalmology therapies market has experienced significant growth recently. It is projected to expand from $3.23 billion in 2025 to $3.69 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.2%. The historical increase can be attributed to progress in retinal disease research, a growing prevalence of chronic eye disorders, the establishment of more ophthalmology specialty clinics, improvements in ocular imaging technologies, and an increase in clinical trial activity for eye diseases.

The market for personalized ophthalmology therapies is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $6.22 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.0%. This expansion throughout the projected timeframe is largely driven by factors such as the increasing authorization of gene and cell therapies, heightened financial commitments towards precision ophthalmology research, the broadening scope of personalized treatment methodologies, the wider integration of sophisticated drug delivery platforms, and an escalating need for solutions aimed at long-term vision retention. Key patterns expected during this period encompass the accelerated creation of gene-based treatments for eye conditions, the increasing utilization of biomarker-informed therapeutic strategies, the expanded application of advanced retinal imaging techniques for selecting appropriate treatments, the spread of targeted drug delivery mechanisms, and a heightened emphasis on individualized disease management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28295&type=smp

What Drivers Are Affecting Demand In The Personalized Ophthalmology Therapies Market?

The increasing occurrence of chronic vision disorders is projected to boost the personalized ophthalmology therapies market moving forward. These disorders are persistent eye conditions that gradually impair vision and often demand continuous management over prolonged periods. A primary reason for the rise in chronic vision disorders is the growing global incidence of diabetes, which leads to complications such as diabetic retinopathy, causing progressive damage to the eyes over time. Personalized ophthalmology therapies offer advantages for chronic vision disorders by devising treatment strategies customized to an individual’s distinct genetic and molecular profile, thereby improving treatment effectiveness and helping to slow the disease’s advancement. For instance, data from the Centers for Disease Control and Prevention (CDC) in May 2024 indicates that without effective measures, cases of diabetic retinopathy are anticipated to increase by 72%, while cataract cases are expected to grow by 87% by 2050. Thus, the escalating prevalence of chronic vision disorders is a key factor driving the growth of the personalized ophthalmology therapies market.

Which Segments Are Gaining Traction In The Personalized Ophthalmology Therapies Market?

The personalized ophthalmology therapies market covered in this report is segmented –

1) By Therapy Type: Gene Therapy, Cell Therapy, Pharmacogenomics, Targeted Drug Delivery, Other Therapy Types

2) By Indication: Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma, Retinitis Pigmentosa, Other Indications

3) By End User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, CRISPR Or Cas9-Based Gene Editing

2) By Cell Therapy: Stem Cell Therapy, Retinal Pigment Epithelial (RPE) Cell Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy

3) By Pharmacogenomics: Drug Response Testing, Genetic Biomarker-Based Therapy, Personalized Drug Dosing

4) By Targeted Drug Delivery: Nanoparticle-Based Delivery, Liposomal Drug Delivery, Hydrogel-Based Delivery Systems

5) By Other Therapy Types: RNA-Based Therapy, Antisense Oligonucleotide Therapy, Peptide-Based Therapy

Which Innovation Trends Are Advancing Developments Within The Personalized Ophthalmology Therapies Market?

Leading companies in the personalized ophthalmology therapies market are concentrating on developing innovative solutions, such as one-time intravitreal gene therapies, to alleviate patient burden and reduce the risk of complications associated with multiple injections. These single-dose intravitreal gene therapies involve a sole injection into the eye’s vitreous cavity, delivering genetic material to address or modify underlying eye disorders and offering enduring treatment effects. For example, in July 2025, Sanofi, a pharmaceutical and healthcare company based in France, announced that the US Food and Drug Administration (FDA) had granted fast track designation for SAR446597. This single-dose intravitreal gene therapy is designed to treat geographic atrophy (GA) caused by age-related macular degeneration (AMD). Its fast-track designation aims to expedite development and regulatory review for serious conditions with unmet medical needs. The therapy introduces genetic material encoding two antibody fragments that block C1s in the classical complement pathway and factor Bb in the alternative pathway. This dual-action mechanism is intended to provide sustained complement suppression in the retina, targeting the disease process while minimizing the requirement for repeated injections.

Who Are The Major Companies Operating In The Personalized Ophthalmology Therapies Market?

Major companies operating in the personalized ophthalmology therapies market are Roche Holding AG, Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Inc., Genentech Inc., Bausch + Lomb Corporation, Johnson & Johnson Vision Care Inc., Carl Zeiss Meditec AG, Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Senju Pharmaceutical Co. Ltd., MeiraGTx Ltd., Beacon Therapeutics, Clearside Biomedical Inc., Adverum Biotechnologies Inc., Ocugen Inc., GenSight Biologics, Nanoscope Therapeutics Inc., 4D Molecular Therapeutics Inc., Coave Therapeutics.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/personalized-ophthalmology-therapies-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Personalized Ophthalmology Therapies Market?

North America was the largest region in the personalized ophthalmology therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized ophthalmology therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Personalized Ophthalmology Therapies Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28295&type=smp

Browse Through More Reports Similar to the Global Personalized Ophthalmology Therapies Market 2026, By The Business Research Company

Ophthalmic Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/ophthalmic-devices-global-market-report

Ophthalmic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/ophthalmic-drugs-global-market-report

Anemia And Other Blood Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795